Core IM | Internal Medicine Podcast #144 RSV & What Makes Vaccine Trials Different: Beyond Journal Club on the RENOIR and AReSVi Trials
Jan 31, 2024
Join guest_name_1, an expert on RSV vaccines and vaccine trials, as they discuss the results of the RENOIR and AReSVi trials. Discover the challenges in creating an RSV vaccine and how to interpret vaccine trials. Explore the development of an RSV vaccine for older adults and the importance of considering patient's health status and risk factors when making vaccination recommendations.
AI Snips
Chapters
Transcript
Episode notes
RSV Risk Higher in Older Adults
- RSV causes more hospitalizations and deaths in adults over 65 than in children.
- Immunity wanes in older adults, making vaccination beneficial despite near universal early childhood exposure.
RSV Vaccine Development Challenges
- Initial RSV vaccines caused antibody dependent enhancement, worsening illness on natural exposure.
- Unlocking the prefusion shape of the F glycoprotein was key to developing effective vaccines.
Key Vaccine Trial Design Factors
- Vaccine trial placebo choice affects perceived efficacy and side effects.
- Confirmed RSV infections are preferred endpoints, while transmission is hard to measure in trials.